Aktis Oncology, Inc. (AKTS) Institutional Ownership & Insider Trading
114 institutions reported holding Aktis Oncology, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 20 insider trades on Form 4 since 2025-10-01.
Source: SEC EDGAR filings · read by EquiReason
AKTSAktis Oncology, Inc.Follow AKTS — free
—
Price chart with a free account
- Market cap
- 874.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Institutions · all 13F filers
quarter to 30 Jun 2026 · filers in both quarters114 institutions held 61.4% of the shares. Across filers that reported both quarters, shares held changed -2.6%.
Largest moves, shares (millions)
Institutional flow by quarter
net shares added or trimmed, millions · filers in both quarters| Quarter | Holders | Shares held, M | Change | Increased | New | Decreased | Closed |
|---|---|---|---|---|---|---|---|
| Jun 26 | 114 | 34 | -2.6% | 27 | 50 | 18 | 6 |
| Mar 26 | 69 | 35 | — | — | — | — | — |
Aktis Oncology, Inc. — questions
- Who owns Aktis Oncology, Inc. stock?
- 114 institutions reported Aktis Oncology, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: MPM BIOIMPACT LLC (8.7%), EcoR1 Capital, LLC (8.7%), Blue Owl Capital Holdings LP (5.5%).
- Are Aktis Oncology, Inc. insiders buying or selling?
- 20 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.
Every figure on this page comes from Aktis Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.